ALPROSTADIL

Search structure
Trade Names:
Synonyms:
Status: Approved (1981)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: C01EA01
UNII: F5TD010360

Structure
InChI Key GMVPRGQOIOIIMI-DWKJAMRDSA-N
Smile CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O
InChI
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C20H34O5
Molecular Weight 354.49
AlogP 3.48
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 13.0
Polar Surface Area 94.83
Molecular species ACID
Aromatic Rings 0.0
Heavy Atoms 25.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Prostanoid EP1 receptor agonist ISBN FDA
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- - - - 17
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Lipid-like ligand receptor (family A GPCR) Prostanoid receptor
3-4 1400 - 22-87 -
Transporter Primary active transporter ATP-binding cassette ABCC subfamily
- 2300 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Macular Degeneration 3 D008268 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 3 D064129 ClinicalTrials
Heart Failure 3 D006333 ClinicalTrials
Optic Neuropathy, Ischemic 2 D018917 ClinicalTrials
Peripheral Arterial Disease 2 D058729 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Respiratory Distress Syndrome 2 D012128 ClinicalTrials
Sexual Dysfunction, Physiological 2 D012735 ClinicalTrials
Peripheral Vascular Diseases 2 D016491 ClinicalTrials
Arteriosclerosis Obliterans 2 D001162 ClinicalTrials

Related Entries

MCS

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
32.98
Injury, poisoning and procedural complications
20.2
Reproductive system and breast disorders
12.81
Product issues
6.26
Vascular disorders
5.39
Psychiatric disorders
3.73
Nervous system disorders
3.49
Musculoskeletal and connective tissue disorders
2.65
Skin and subcutaneous tissue disorders
2.17

Cross References

Resources Reference
CAS NUMBER 745-65-3
ChEBI 15544
ChEMBL CHEMBL495
DrugBank DB00770
DrugCentral 138
EPA CompTox DTXSID9022578
FDA SRS F5TD010360
Human Metabolome Database HMDB0001442
Guide to Pharmacology 1882
KEGG C04741
PDB XPG
PubChem 5280723
SureChEMBL SCHEMBL33317
ZINC ZINC000003813088
CONTENTS